Abstract
Fibrosis stage was assessed by liver biopsy scores, FibroScan scores, or FibroTest scores. Post-treatment relapse shown through post-treatment week 12 for 3D+RBV arm and through post-treatment week 4 for TPV+pegIFN/RBV arm. Non-virologic treatment failure includes premature drug discontinuation and missing SVR data. *P-value ≤ 0.05 for the comparison with the TPV+pegIFN/RBV arm. For SVR4, P-value is based on logistic regression. Fisher's exact test was used for comparison of AE frequency.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
